Drug Trial Radar · NCT05352750
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
Last checked: Nov 20, 2026Latest source record: Feb 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
42
Actual
Start
Apr 20, 2022
Primary completion
Jun 30, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Sonnet BioTherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 29, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.
Conditions
- Advanced Solid Tumor
- Soft Tissue Sarcoma Adult
Interventions
SON-1010Biological
SON-1010 is a recombinant, single-chain, unmodified human rIL-12 joined by a flexible linker to the fully human albumin binding (FHAB) domain that "hitch-hikes" on serum albumin for transport to the tumor microenvironment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of SON-1010Time frame: Through study completion, an average of 1 year
- To establish the maximum tolerated dose (MTD) of SON-1010Time frame: Through study completion, an average of 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sarcoma Oncology Center
Santa Monica, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.